The Best Combination Treatment of Patients with Advanced Nasopharyngeal Carcinoma.

F. Li,X. Zhang,L. Chen,H. Chen,B. Liang,Y. Dai,G. Ma,J. Zheng

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e16018

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:e16018 Background: To evaluate Radiotherapy, Platinum, 5-FU and Nimotuzumab combine therapy in treatment of advanced nasopharyngeal carcinoma. Methods: From January 2010 until October 2010, 268 patients with pathologically diagnosed advanced Nasopharyngeal carcinoma, stage II to IV with partial metastases combine treated with Nimotuzumab, chemo-radiotherapy were collected. Among 268 patients 241 were qualified for analysis by SAS program. Generally, patients were receiving a total dose of 45Gy-72Gy radiotherapy, and mainly receiving combination of chemotherapy program of Platinum, and all patients were receiving 100-200mg of Nimotuzumab treatment over the same period, once a week. Results: There were 241 cases medical records can be analyzed. Patients aged 37-75 years-old with median age of 60.2. Male and female ratio was 3.46:1. Pathology diagnosed as squamous cell carcinoma. Cancer staged as IV, III and II were 38.2%, 53.7% and 9.1%, and with 64.73% of them with metastasis. Seven patients(2.91%) had adverse events which considering doubt as due to treatment, including chills, fever, rash, oral mucositis and allergy. No patient had significant fatigue, thrombocytopenia, decreased white blood cells count. No other sensory abnormalities, such as sepsis, herpes zoster, bilirubin and heart discomfort were observed. Conclusions: Nimotuzumab combined with chemo-radiotherapy for patients with advanced carcinoma is well tolerated and safe. Radiotherapy, Platinum, 5-FU and Nimotuzumab combine therapy can be considered as the best treatment regimen for patients with advanced nasopharyngeal carcinoma.